Clinical Research Directory
Browse clinical research sites, groups, and studies.
Efficacy and Safety of Rimegepant for Acute Dizziness
Sponsor: Shi Tianming
Summary
This study aims to explore the efficacy and safety of rimegepant for acute dizziness, including vestibular migraine (VM) and benign recurrent vertigo (BRV), through a multicenter, randomized controlled clinical trial. This study addresses the urgent clinical need for effective therapies for acute dizziness. Additionally, we will dynamically observe the changes in calcitonin gene-related peptide (CGRP) levels before and after treatment and explore the predictive value of CGRP levels for treatment efficacy and the prognosis of recurrence in patients. This study aims to provide a scientific basis to improve clinical management strategies for acute dizziness.
Official title: A Multicenter Randomized Controlled Trial on the Efficacy and Safety of Rimegepant in the Treatment of Acute Dizziness
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
370
Start Date
2026-03-20
Completion Date
2028-06-30
Last Updated
2026-02-27
Healthy Volunteers
No
Conditions
Interventions
Rimegepant 75mg Orally Disintegrating Tablets (ODT)
A single dose of Rimegepant orally disintegrating tablets (75 mg) combined with betahistine mesylate (12 mg) administered orally.
Betahistine Mesylate tablet
A single dose of betahistine mesylate (12 mg) administered orally.